

STAAR SURGICAL CO
Form NT 10-K
March 18, 2010

UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION

SEC File Number 0-11634
CUSIP Number 852312305

Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one): Form 10-K Form 20-F Form 11-K Form 10-Q
 Form 10-D Form N-SAR Form N-CSR

For Period Ended: January 1, 2010

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: _____

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I — REGISTRANT INFORMATION

STAAR SURGICAL COMPANY

Address of Principal Executive Office (Street and Number)

1911 Walker Avenue

City, State and Zip Code

Monrovia, California 91016

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

- x (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
- (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

As described in its Current Report on Form 8-K/A filed on March 9, 2010, the Registrant completed the divestiture of all of its interest in Domilens GmbH, its German distribution subsidiary, on March 2, 2010. Because of the need to prepare full financial reporting of the divestiture as an event subsequent to the fiscal year ended January 1, 2010, and the need to analyze and describe fully the effect of the divestiture on STAAR's business and financial condition, the Registrant could not complete its financial statements and related disclosures prior to the prescribed filing deadline for the 10-K.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Charles Kaufman, Vice President and General Counsel	(626)	303-7902
(name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s). x Yes o No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? x Yes o No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

STAAR Surgical Company has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 18, 2010

By /s/ Deborah Andrews
Deborah Andrews
Vice President and Chief Financial
Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

-2-

INFORMATION REQUIRED BY PART IV ITEM 3

The preliminary, unaudited, condensed consolidated statement of operations set forth below shows anticipated changes in results of operations that will be reflected in the earnings statement of the Registrant's Annual Report on Form 10-K for the three months and fiscal year ended January 1, 2010. Additional information regarding anticipated changes in results of operations has been provided in a press release published on March 2, 2010 (the "Press Release"). The Press Release has been furnished as Exhibit 99.1 to the Registrant's Current Report on Form 8-K filed on March 8, 2010, which is incorporated herein by this reference.

STAAR Surgical Company
Condensed Consolidated Statements of Operations

(In 000's except for per share data)

Unaudited

	% of	Three Months Ended		% of	January	Year Ended		% of	January
		January	January			January	January		
	Sales	1,	2,	Sales	2,	1,	2,	Sales	2,
		2010	2009		2009	2010	2009		2009
Net sales	100.0%	\$ 19,831	100.0%	\$ 18,157	100.0%	\$ 75,345	100.0%	\$ 74,894	
Cost of sales	44.3%	8,777	42.9%	7,797	44.4%	33,452	46.4%	34,787	
Gross profit	55.7%	11,054	57.1%	10,360	55.6%	41,893	53.6%	40,107	
Selling, general and administrative expenses:									
General and administrative	22.7%	4,493	23.6%	4,288	21.4%	16,119	21.0%	15,730	
Marketing and selling	32.6%	6,473	35.4%	6,426	32.2%	24,257	36.1%	27,053	
Research and development	7.6%	1,498	10.9%	1,974	7.8%	5,893	10.6%	7,938	
Other expenses	36.3%	7,209	32.6%	5,923	9.6%	7,209	13.0%	9,773	
Total selling, general and administrative expenses	99.2%	19,673	102.5%	18,611	71.0%	53,478	80.7%	60,494	
Operating loss	-43.5%	(8,619)	-45.4%	(8,251)	-15.4%	(11,585)	-27.1%	(20,387)	
Other income (expense):									
Interest income	0.1%	24	0.1%	22	0.1%	60	0.2%	160	
Interest expense	-3.1%	(618)	-1.4%	(256)	-2.4%	(1,801)	-1.2%	(901)	
Loss on foreign currency	-1.0%	(200)	-2.0%	(367)	0.0%	-	-0.9%	(696)	
Other income, net	0.8%								